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Abstract Scleroderma (systemic sclerosis, SSc) is a fibrot-
ic disease for which there is no therapy. CCN2 (connective
tissue growth factor, CTGF) is a marker and mediator of
fibrosis. Previously, it has been shown that thrombin
induces CCN2 expression in fibroblasts. In a recent
fascinating report, Bogatkevich et al. (Arthritis Rheum
60:3455–3464, 2009) show that dabigatran, an inhibitor of
thrombin action, blocks the overexpression of CCN2 by
scleroderma fibroblasts and reverses the contractile pheno-
type of these cells. These results strongly suggest that
dabigatran may be a potential antifibrotic drug for the
treatment of fibrosing diseases such as scleroderma.
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SSc is a prototypical multisystem disease with a significant
fibrotic component; patients often die due to lung fibrosis
(Varga and Abraham 2007). There is no therapy for SSc;
however, recent studies have shown that, as for other
fibroproliferative diseases, a particular type of differentiated
fibroblast, termed the myofibroblast, contributes to scar
formation in this disease (Chen et al. 2005). Myofibroblasts
are characterized by an increased proliferative and contrac-
tile capacity and abundant expression of α-smooth muscle
actin (α-SMA), collagens, and other ECM proteins (Hinz et
al. 2007). Overexpression of CCN2 is also considered to be
a key marker of fibrotic fibroblasts; the levels of CCN2
expression correlate well with the severity of fibrosis in SSc
(Leask 2004; Dziadzio et al. 2005; Leask et al. 2009). Thus,
targeting the action of the myofibroblast is essential for
developing rational therapies for SSc. Of note, it is essential
to remember that, in spite of the fact that in vitro the potent
pro-fibrotic cytokine transforming growth factor β (TGFβ)
induces α-SMA expression and myofibroblast differentia-
tion, blocking canonical TGFβ signaling does not affect the
α-SMA or CCN2 expression in scleroderma fibroblasts
(Leask 2006; Chen et al. 2006).
When applied to lung fibroblasts, thrombin, a multifunc-
tional serine protease and a key enzyme of blood
coagulation that catalyzes the conversion of fibrinogen to
fibrin (Green 2006), induces myofibroblast formation and
CCN2 expression (Chambers et al. 2000; Bogatkevich et al.
2001). Dabigatran is a selective direct thrombin inhibitor
that reversibly binds to thrombin and prevents the cleavage
of fibrinogen to fibrin (Sorbera et al. 2005). In a recent
study by Bogatkevich and colleagues, dabigatran blocked
thrombin-induced myofibroblast differentiation, and sup-
pressed CCN2, α-SMA, and collagen overexpression by
scleroderma fibroblasts.
Previously, it was shown that inhibition of endothelin-1,
but not canonical TGFβ signaling, reverses the α-SMA and
CCN2 overexpression by SSc fibroblasts (Shiwen et al.
2004, 2007; Chen et al. 2006). Thrombin itself has been
demonstrated to induce endothelin-1 (Lepailleur-Enouf et
al. 2000). These data suggest that thrombin activity may be
responsible for the overexpression of endothelin-1, α-SMA
and CCN2 in SSc fibroblasts and thus for the fibrosis
observed in this disease.
This study suggests that dabigatran might prove to be a
promising drug for the treatment of fibrotic conditions
where there is thrombin overexpression. However, studies
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